胰腺癌生物标志物的进展。
Advances in pancreatic cancer biomarkers.
作者信息
Hasan Syed, Jacob Rojymon, Manne Upender, Paluri Ravi
机构信息
University of Alabama at Birmingham, USA.
出版信息
Oncol Rev. 2019 Feb 1;13(1):410. doi: 10.4081/oncol.2019.410. eCollection 2019 Jan 14.
Abstract
Biomarkers play an essential role in the management of patients with invasive cancers. Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced presentation and limited therapeutic options. This is further complicated by absence of validated screening and predictive biomarkers for early diagnosis and precision treatments respectively. There is emerging data on biomarkers in pancreatic cancer in past two decades. So far, the CA 19-9 remains the only approved biomarker for diagnosis and response assessment but limited by low sensitivity and specificity. In this article, we aim to review current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer.
摘要
生物标志物在侵袭性癌症患者的管理中起着至关重要的作用。胰腺导管腺癌（PDC）由于就诊时病情已进展且治疗选择有限，预后较差。由于分别缺乏用于早期诊断和精准治疗的经过验证的筛查和预测生物标志物，情况变得更加复杂。在过去二十年中，关于胰腺癌生物标志物有了新的数据。到目前为止，CA 19-9仍然是唯一被批准用于诊断和反应评估的生物标志物，但受低敏感性和特异性的限制。在本文中，我们旨在综述当前和未来的生物标志物，这些生物标志物有可能成为胰腺癌早期诊断、预测和预后指征的关键工具。
相似文献
1
Advances in pancreatic cancer biomarkers.胰腺癌生物标志物的进展。
Oncol Rev. 2019 Feb 1;13(1):410. doi: 10.4081/oncol.2019.410. eCollection 2019 Jan 14.
2
Current and future biomarkers for pancreatic adenocarcinoma.胰腺癌的当前及未来生物标志物
Tumour Biol. 2017 Jun;39(6):1010428317692231. doi: 10.1177/1010428317692231.
3
Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.胰腺癌的生物标志物：诊断、预后和预测。
Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea.
4
Biomarkers in pancreatic ductal adenocarcinoma.胰腺导管腺癌的生物标志物。
Clin Transl Oncol. 2017 Dec;19(12):1430-1437. doi: 10.1007/s12094-017-1691-5. Epub 2017 Jun 14.
5
Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.血浆循环肿瘤 DNA 在胰腺腺癌的筛查、诊断、预后、治疗和随访中的应用：系统评价。
Cancer Treat Rev. 2020 Jul;87:102028. doi: 10.1016/j.ctrv.2020.102028. Epub 2020 May 4.
6
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.胰腺癌的诊断、预后和预测生物标志物。
J Surg Oncol. 2013 Jan;107(1):15-22. doi: 10.1002/jso.23192. Epub 2012 Jun 21.
7
Progress on diagnostic and prognostic markers of pancreatic cancer.胰腺癌诊断和预后标志物的研究进展。
Oncol Res. 2023 Apr 10;31(2):83-99. doi: 10.32604/or.2023.028905. eCollection 2023.
8
The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.生物标志物在胰腺腺癌管理中的临床应用
Semin Radiat Oncol. 2014 Apr;24(2):67-76. doi: 10.1016/j.semradonc.2013.11.007.
9
Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.无细胞游离 DNA 甲基化：胰腺癌生物标志物发现的新前沿。
Genes (Basel). 2019 Dec 23;11(1):14. doi: 10.3390/genes11010014.
10
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.胰胆恶性肿瘤的诊断和治疗生物标志物
World J Gastrointest Endosc. 2016 Feb 10;8(3):128-42. doi: 10.4253/wjge.v8.i3.128.
引用本文的文献
1
Elevated expression of transferrin receptor-1 in pancreatic cancer: clinical implications and prognostic significance.转铁蛋白受体-1在胰腺癌中的高表达：临床意义及预后价值
Clin Exp Med. 2025 Aug 28;25(1):307. doi: 10.1007/s10238-025-01847-0.
2
Gene Methylation in Tumors with Low CD8 T-Cell Infiltration Drives Positive Prognostic Overall Survival Responses in Pancreatic Ductal Adenocarcinoma.低CD8 T细胞浸润肿瘤中的基因甲基化驱动胰腺导管腺癌的总体生存预后良好。
Int J Mol Sci. 2025 Jun 10;26(12):5567. doi: 10.3390/ijms26125567.
3
Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation.捕捉胰腺导管腺癌肿瘤微环境的异质性：用于药物筛选和血管生成评估的新型三重共培养球体
Cells. 2025 Mar 18;14(6):450. doi: 10.3390/cells14060450.
4
Transcriptomic profiling of blood platelets identifies a diagnostic signature for pancreatic cancer.血小板的转录组分析确定了胰腺癌的诊断特征。
Br J Cancer. 2025 Jun;132(10):937-946. doi: 10.1038/s41416-025-02980-z. Epub 2025 Mar 25.
5
Unveiling the Potential Role of Hesperetin and Emodin as a Combination Therapy to Inhibit the Pancreatic Cancer Progression against the C-Met Gene.揭示橙皮素和大黄素联合治疗对抑制胰腺癌进展及针对C-Met基因的潜在作用。
Protein Pept Lett. 2025;32(4):280-298. doi: 10.2174/0109298665363165250225100109.
6
Advances in Endoscopic Ultrasound in Pancreatic Cancer Screening, Diagnosis, and Palliative Care.胰腺癌筛查、诊断及姑息治疗中内镜超声的进展
Biomedicines. 2024 Dec 31;13(1):76. doi: 10.3390/biomedicines13010076.
7
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance.LGR5：癌症转移和化疗耐药性的新兴治疗靶点。
Cancer Metastasis Rev. 2025 Jan 17;44(1):23. doi: 10.1007/s10555-024-10239-x.
8
Biosensors for Cancer Biomarkers Based on Mesoporous Silica Nanoparticles.基于介孔硅纳米粒子的癌症生物标志物生物传感器。
Biosensors (Basel). 2024 Jun 30;14(7):326. doi: 10.3390/bios14070326.
9
Recent Trends and Innovations in Bead-Based Biosensors for Cancer Detection.基于珠粒的用于癌症检测的生物传感器的最新趋势和创新。
Sensors (Basel). 2024 May 1;24(9):2904. doi: 10.3390/s24092904.
10
An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.一种综合计算生物学方法确定了TRIP13在胰腺癌中的关键作用。
Comput Struct Biotechnol J. 2023 Nov 17;21:5765-5775. doi: 10.1016/j.csbj.2023.11.029. eCollection 2023.
本文引用的文献
1
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.胃肠道癌症中的表观遗传学标志物：现状与临床展望。
Semin Cancer Biol. 2018 Aug;51:36-49. doi: 10.1016/j.semcancer.2017.12.004. Epub 2017 Dec 15.
2
Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma.血浆中游离DNA启动子高甲基化作为胰腺腺癌患者生存的预测标志物。
Oncotarget. 2017 Sep 30;8(55):93942-93956. doi: 10.18632/oncotarget.21397. eCollection 2017 Nov 7.
3
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.组织采集用于生物标志物研究中的挑战识别：Q-CROC-03 新辅助乳腺癌转化试验经验。
Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.
4
Epidemiology of pancreatic adenocarcinoma.胰腺腺癌的流行病学
Chin Clin Oncol. 2017 Jun;6(3):24. doi: 10.21037/cco.2017.06.32.
5
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
6
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).靶向肿瘤基质：聚乙二醇化重组人透明质酸酶（PEGPH20）的生物学特性与临床开发
Curr Oncol Rep. 2017 Jul;19(7):47. doi: 10.1007/s11912-017-0608-3.
7
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.免疫组化 hENT1 表达作为接受吉西他滨为基础的辅助化疗的胰腺导管腺癌患者的预后生物标志物。
Br J Surg. 2017 Mar;104(4):328-336. doi: 10.1002/bjs.10482.
8
Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.磷脂酰肌醇蛋白聚糖-3和细胞角蛋白19是与胰腺导管腺癌转移及预后不良相关的标志物。
Cancer Biomark. 2016;17(4):397-404. doi: 10.3233/CBM-160655.
9
Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies.不同类型癌症患者中低水平微小RNA-218表达的预后意义：来自已发表研究的证据
Medicine (Baltimore). 2016 Sep;95(37):e4773. doi: 10.1097/MD.0000000000004773.
10
Prognostic value of PDL1 expression in pancreatic cancer.PDL1表达在胰腺癌中的预后价值。
Oncotarget. 2016 Nov 1;7(44):71198-71210. doi: 10.18632/oncotarget.11685.
Zotero 插件